Company news: Lilly and Amgen

Share this article:
Greater marketing and sales costs hurt Lilly's third-quarter profits, which slipped 6% to $1.2 billion. The company said sales rose 20% or more for several products during the quarter, including Cymbalta, Humalog, Strattera and Forteo, along with animal health products, but was hit by costs associated with healthcare reform, which reduced revenue by around $330 million and increased administrative expenses by around $135 million for the first nine months of the year.

Amgen is laying off 380 employees from its R&D division, Bloomberg reported, after slashing research spending 26% during the second quarter to accommodate the expense associated with moving three pipeline candidates into larger clinical trials.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.